Sphenopalatine Ganglion Stimulation in the Pathway CH-1 Study Reduces Headache Burden Before and After Sustained Periods of Cluster Attack Remission

BUDAPEST, Hungary, April 8, 2015 /PRNewswire/ — During the world congress of controversies in Neurology, CONy, Autonomic Technologies[TM] presented long term data* (18 months results) on a segment of the CH-1 study patients experiencing Cluster Headache Remission periods. While Sphenopalatine Ganglion (SPG) stimulation with the Pulsante[TM] microstimulator has already shown safety and efficacy on chronic cluster headache, long-term benefits of SPG stimulation in cluster patients with remission suggest that the therapy is beneficial during the episodic phase of patients’ cluster bouts.

“This data strongly suggest that SPG stimulation could be beneficial also to episodic cluster patients”, commented Prof. Miguel Lainez, Head of Neurology Department at Catholic University of Valencia and Professor of Neurology in the Catholic University of Valencia who presented the data on March 28th.

Pulsante microstimulator is the first electroceutical device that has documented efficacy in a long term RCT for the treatment of cluster headache. The Pulsante microstimulator is MR Conditional since 2012. The device is inserted through the gum with a minimally invasive technique that leaves no visible scars.

Autonomic Technologies 

Autonomic Technologies, Inc. (ATI[TM]) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company’s initial product, the Pulsante microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is also under an IDE study in the US for the treatment of chronic cluster headache.  

ATI is headquartered in the San Francisco Bay Area and is backed by blue chip investors: Kleiner Perkins Caufield and Byers, InterWest Partners, Versant Ventures, Novartis Ventures, Aberdare Ventures, and the Cleveland Clinic.  http://www.pulsante.eu

Contact:
Eva Birle
+49(0)891395782711
birle@bskom.de

*Poster Presentation at 9th CONy Congress, Budapest, March 28th 2015 

Latin American Contract Research Organizations Set to Get More Local Outsourcing Opportunities

– Currently, multinational companies outsource a larger proportion of their clinical trials than local firms, finds Frost & Sullivan

SAO PAULO, April 7, 2015 /PRNewswire/ — As market penetration stood at only 64 percent in 2013, huge opportunities exist for contract research organizations (CROs) to expand their market share in Latin America (LATAM). Local contracts, which accounted for 21.6 percent of the total market size in 2013, will begin to contribute more to overall revenues. The local development of biosimilars, domestic pharmaceutical companies’ plans to increase the number of clinical trials to comply with regulations, and focus on geographic expansion will give rise to more local contracts for CROs in the region.

Research

Research

Photo – http://photos.prnewswire.com/prnh/20150407/196999

New analysis from Frost & Sullivan, Latin American Contract Research Organization Market (http://www.frost.com/p849), finds that the market earned revenues of $438.5 million in 2013 and estimates this to reach $661.3 million in 2019 at a compound annual growth rate of 7.1 percent. The study covers phase I, phase II, phase III and late phase clinical development as well as biostatistics, central laboratory services and data management. Health economics studies, a part of late phase trials, will gain significant traction in the coming years, since they are utilized while deciding which new molecules to include in the list of reimbursed drugs considered by public health services and private insurance plans.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/LA_PR_FValente_P849-52_27Mar15.

“Multinational pharmaceutical companies tend to outsource about 70 percent of their trials by adopting either a fully outsourced or function-to-function model,” said Frost & Sullivan Healthcare Consultant Sanjeev Kumar. “However, local pharmaceutical companies have lower outsourcing rates that range from 50 to 70 percent in countries across LATAM.”

In Argentina and Brazil, regulatory issues have restrained clinical development, thereby dampening the prospects of CROs in the region. Bottlenecks in the Agencia Nacional de Vigilancia Sanitaria (ANVISA) submission and approval processes have meant that protocol approval takes 12 to 15 months in Brazil and an average of 6 months in Argentina.

In addition, limited outsourcing among big pharmaceutical clients that can conduct in-house R&D and clinical drug testing has restricted CRO market growth. Nevertheless, as large, well-established CROs have begun to use specialized research technologies that can cater to the rising demand for drug development, pharmaceutical clients’ reliance on in-house R&D is likely to reduce considerably. Along with this trend, the rise of innovative therapeutic options as well as the need for increased drug efficacy and safety will promote market development.

“In order to better serve and become the preferred partner of bio-pharmaceutical companies, CROs in LATAM must make an effort to expand their range of services,” noted Kumar. “Mergers and acquisitions with local CROs will be a cost-effective approach to achieve this end.”

Latin American Contract Research Organization Market is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Global Diabetes Drug Delivery Market, Global CRO Market, Global Stem Cell Market, and Global Infectious Disease Diagnostics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Latin American Contract Research Organization Market
P849-52

Contact:
Francesca Valente
Corporate Communications – Latin America
P: +54 11 4777 5300
F: +54 11 4777 5300
E: francesca.valente@frost.com 

http://www.frost.com

Photo – http://photos.prnasia.com/prnh/20150407/8521502174

European Hospitals Will Move from Single-Use to Reusable Procedure Trays and Packs

— The trend is catching on as hospitals try to make their operating rooms greener to reduce environmental impact, finds Frost & Sullivan

LONDON, April 7, 2015 /PRNewswire/ — Increasing procedure volumes have been fuelling the adoption of custom procedure trays and packs (CPTP) in Western and Eastern Europe. In part, the expanding aging population, which is more likely to develop chronic wounds as they have more medical issues affecting their general health and mobility, has been responsible for the growth in procedures and the resultant expansion of the CPTP market.

Frost & Sullivan

Frost & Sullivan

Logo – http://photos.prnewswire.com/prnh/20150407/196956LOGO

New analysis from Frost & Sullivan, Western and Eastern European Custom Procedure Trays and Packs (CPTP) Market, finds that the market earned revenues of $769.4 million in 2014 and estimates this to reach $1131.4 million in 2019. The study covers surgical and minor procedure trays and packs.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_AZanchi_MAC5-54_20Mar15

CPTP offer off-the-shelf convenience to hospitals, lower costs, and lead to more efficient operating rooms (ORs) with faster turnaround times between operations. Additionally, these products enable inventory reduction, easy storage, and simplified delivery schedules.

“In Western and Eastern Europe, single-use CPTP have particularly gained traction due to the stricter enforcement of infection-control measures within the hospital environment,” said Frost & Sullivan Healthcare Senior Research Analyst Parthasarathy Raghava. “For hospitals in these regions, these kits have been a natural choice as they ensure both compliance with safety standards and control over nosocomial and iatrogenic infections in the OR.”

However, with more hospitals involved in greening the OR, the future will see an emphasis on reusable and reprocessable kits rather than single-use or disposable kits. Thus, market participants that provide comprehensive CPTP services as well as reprocessing and serialization services will be in the best position to acquire new customers.

Nevertheless, certain challenges will continue to trouble market participants in Western and Eastern Europe. For one, the lack of standard regulations mandating the adoption of procedure packs will curtail usage rates in these regions. Furthermore, new entrants’ tendency to undercut prices to strengthen their foothold in the market will create pricing pressures and dampen overall market revenues.

“To remain competitive, market participants in Western and Eastern Europe will have to find a sweet spot between customizing trays and packs according to end-user preferences and standardizing these products to control costs,” noted Raghava. “Perhaps, standardizing only basic commodity items in packs is an appropriate starting point for CPTP providers to achieve these ends.”

Western and Eastern European Custom Procedure Trays and Packs (CPTP) Market is part of the Advanced Medical Technologies Growth Partnership Service program. Frost & Sullivan’s related studies include: Western European Percutaneous Coronary Intervention (PCI) Devices Market, Western European Infant Care Solutions Market, Global Orthopaedic Implant Market, and Global Wound Care Market Outlook. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com 
http://www.frost.com 

Photo – http://photos.prnasia.com/prnh/20150407/8521502165

Sentinel Studies Find New Microcurrent Generating Wound Dressing Effective in Disrupting Bacterial Biofilms

TEMPE, Ariz., April 6, 2015 /PRNewswire/ — Procellera® from Vomaris Innovations, Inc. (now available through Arthrex as JumpStart™) – the only wound dressing powered by Advanced Microcurrent Technology™, has been found to significantly disrupt bacterial biofilms, according to two new published research studies in PLoS ONE and the Journal of Wound Care1-2.

Studies conducted at The Ohio State University (OSU) Wexner Medical Center, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and its Diagnostics and Translational Research Center (DTRC) both confirmed significant anti-biofilm efficacy of Procellera Technology. Bacterial biofilms are complex networks of microorganisms bound together and covered with a slimy protective barrier. They can be found in living tissues, indwelling medical devices, and implants. Biofilm-associated bacteria are extremely resistant to antibiotics and have been implicated in wound infections, resulting in delayed healing, poor clinical outcomes and significant healthcare costs.

In the OSU study, researchers evaluated the effects of Procellera / JumpStart technology to better understand its antimicrobial properties, particularly related to the disruption of Pseudomonas aeruginosa. This bacterial species is often present in chronic wound infections and readily forms biofilm, making it extremely difficult to treat effectively with available antibiotics.

“This work presents clear evidence that this wireless electroceutical dressing disrupts bacterial biofilm,” said Chandan K Sen, Ph.D., Professor of Surgery and Director of the Comprehensive Wound Center at OSU Wexner Medical Center. “Our findings introduce the option of a new affordable technology platform to fight chronic wound infection in which bacterial biofilms are abundant.”

Several mechanisms behind the ability of this Advanced Microcurrent Technology to disrupt the formation of bacterial biofilms were identified:

  • First, the microcurrent technology aided the generation of superoxide radicals, chemical compounds that are produced by white blood cells in the body with the goal to fight infection.
  • Second, researchers discovered that the microcurrents significantly impaired the activity of glycerol-3-phosphate dehydrogenase (GPDH), an electrically sensitive enzyme that is required for bacterial respiration and metabolism.
  • Finally, the research found that the microcurrents disrupted some key antimicrobial resistance genes, silenced some key redox-sensitive, quorum sensing genes and interfered with production of bacteria signaling molecules, thus preventing the bacteria from forming the complex networks that make up biofilms.

Because bacterial biofilms are known to compromise production of antimicrobial superoxide radicals by immune cells, weakening the ability of the body to fight infection, the study’s observation that Procellera initiated spontaneous generation of superoxide radicals is particularly significant.

Research performed at DTRC and HJF studied the anti-biofilm properties of Procellera Technology against ten clinical wound pathogens in a poloxamer biofilm model customized to evaluate the bioelectric dressing. Investigators demonstrated Procellera / JumpStart’s effectiveness against biofilms across multiple species of clinical wound pathogens, with up to a thousand-fold inhibition of microbial growth in several species when compared to controls. This observation is consistent with the observations reported independently from OSU.

“We are very encouraged by the implications of these results for wound care, which showed that this electroceutical dressing was effective in inhibiting growth of both mono- and multi-species biofilms, including multi-drug resistant strains,” said Dr. Mina Izadjoo, principal investigator for the DTRC/HJF study.

“Bacterial biofilms can dramatically impede wound healing and penetrate deeper into a wound bed to further infect implanted devices,” said Michael Nagel, President and Chief Executive Officer of Vomaris Innovations, Inc. “Because of their resistance to treatment, biofilms present a significant challenge in today’s healthcare environment. We, at Vomaris, are extremely pleased by these latest findings by two independent laboratories about this Technology’s ability to inhibit and disrupt biofilms and the significant implications this has for infection control and wound healing.”

PLoS One study co-authors included Jaideep Banerjee, Piya Das Ghatak, Sashwati Roy, Ph.D., Savita Khanna, Ph.D., Craig Hemann, Jay L Zweier, M.D., and Daniel Wozniak, Ph.D. of The Ohio State University. The study was supported in part by the National Institutes of Health: Grant Numbers GM077185, GM069589 and DOD W81XWH-11-2-0142 to CKS; NIH NR013898 to CKS and DJW; and in part by NIH DK076566 to SR and NIH R01AI097511 to DJW.

Co-authors of the Journal of Wound Care article included Hosan Kim, Ph.D. The study was supported by Vomaris.

About Vomaris Innovations
Vomaris Innovations, Inc. is an electroceutical company specializing in microcurrent-generating solutions for the wound care market and beyond. Utilizing electricity to mimic the body’s own physiologic electric currents, which are essential for skin repair and wound healing, Vomaris’ core technology platform employs imbedded microcell batteries that generate microcurrents in the presence of a conductive medium to harness the power of electricity to support healing.

Vomaris’ flagship product, Procellera® Antimicrobial Wound Dressing is the only wound dressing in the world powered by Advanced Microcurrent Technology. It is a new generation solution for wound and incisional care with demonstrated broad-spectrum antimicrobial efficacy3 and the ability to promote wound healing4, and is available exclusively through Arthrex as JumpStart Technology with Advanced Microcurrent Healing.

Procellera / JumpStart is currently used in multiple acute and chronic wound care settings, including clinical, animal and consumer health. The company’s ongoing mission is to develop and deliver evidence-based, patient-focused and cost-effective solutions, backed by a commitment to quality and innovation for the improvement of lives.

About Arthrex
Arthrex, Inc. is a global medical device company and leader in new product development and medical education in orthopaedics. With a corporate mission of helping surgeons treat their patients better, Arthrex has pioneered the field of arthroscopy and developed more than 8,500 innovative products and surgical procedures to advance minimally invasive orthopaedics worldwide. Arthrex remains dedicated to delivering uncompromising quality to the healthcare professionals who use its products, and ultimately, the millions of patients whose lives these products impact.

  1. Kim H, Izadjoo MJ. Antibiofilm efficacy evaluation of a bioelectric dressing in mono- and multi-species biofilms. J Wound Care 2015; 24 Suppl 2:S10-4.
  2. Banerjee J, Ghatak PD, Roy S, Khanna S, Hemann C, Deng B, et al. (2015) Silver-Zinc Redox-Coupled Electroceutical Wound Dressing Disrupts Bacterial Biofilm. PLoS ONE 10(3): e0119531. doi:10.1371/journal.pone.0119531
  3. Kim H, Makin I, Skiba J, Ho A, Housler G, Stojadinovic A, Izadjoo M. Antibacterial Efficacy Testing of a Bioelectric Wound Dressing Against Clinical Wound Pathogens.  The Open Microbiology Journal 2014; 8:15-21.
  4. Banerjee J, Ghatak P, Roy S, Khanna S, Sequin EK, Bellman K, Dickinson BC, Suri P, Subramaniam V, Chang CJ, Sen CK.  Improvement of human keratinocyte migration by a redox active bioelectric dressing. PLOS ONE. 2014; 9(3).

Pyrexar Medical Acquires Hyperthermia Assets of BSD Medical

— Promising Cancer Treatment Technology Now Under New Leadership

SALT LAKE CITY, April 3, 2015 /PRNewswire/ — Pyrexar Medical begins operations today after completing the acquisition of hyperthermia assets held by Perseon (NASDAQ:PRSN), formerly BSD Medical (NASDAQ:BSDM). This acquisition includes substantially all hyperthermia assets, products, services and related intellectual property.

BSD-500 Hyperthermia System

BSD-500 Hyperthermia System

Photo – http://photos.prnewswire.com/prnh/20150402/196321

Medical device industry veteran Mark Falkowski has been named Chief Executive Officer bringing to Pyrexar more than 30 years of successful executive leadership experience with prominent medical companies like GE Healthcare, Imatron, Carestream and OEC/Diasonics.

Mr. Falkowski recruited seasoned capital equipment executives, A. Robert Depalma, Brian Chard, Rex Harmon and Drew Wilkens. Also joining, former Perseon employees Paul Turner, Ray Lauritzen, Richard Faux, Dennis Bradley and a group of highly trained system design, production and customer support team members directly associated with the hyperthermia product line. The new group’s goal is to build a sales and customer focused company.

Mr. Falkowski said: “New minimally invasive treatment technologies are vital to winning the fight against cancer and I look forward to taking an active part in bringing this important cancer fighting medical technology to market.”

Pyrexar will be presenting and exhibiting at the upcoming Society for Thermal Medicine Annual Meeting in Orlando, FL (April 14-17, 2015).

ABOUT PYREXAR MEDICAL:

With the acquisition of BSD Medical assets, Pyrexar Medical takes its place as pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity of healthy tissues.

Multi-center clinical trials in the US, Europe and Asia over the past 30 years document dramatic improvement in survival rates when PYREXAR HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, high risk soft tissue sarcoma, melanoma and other malignancies.

Pyrexar Medical is based in Salt Lake City, UT, USA. For more information please visit our web page at: pyrexar.com

Pyrexar Medical Media Contact:
Drew Wilkens
VP of Digital Marketing
+1-844-797-3927
drew.wilkens@pyrexar.com

Photo – http://photos.prnasia.com/prnh/20150403/8521502127

Singapore’s Vibrant Healthcare Industry an Attractive Market for Advanced Diagnostic Imaging Services, says Frost & Sullivan

– Consumer demand for high-quality services bolsters innovation

SINGAPORE, March 30, 2015 /PRNewswire/ — Singapore’s private outpatient diagnostic imaging services market is receiving a huge boost from a combination of factors including a growing aged population, higher prevalence of non-communicable diseases, and the influx of medical tourists. An estimated 80 percent of the primary healthcare services in the country are provided by private practitioners and the remaining by government polyclinics. In response to the substantial opportunities, device manufacturers are focusing their efforts on developing sophisticated imaging technologies and offering quality output.

New analysis from Frost & Sullivan, Singapore Private Outpatient Diagnostic Imaging Services Market (http://www.frost.com/q293927029), finds that the market earned revenues of US$127.8 million in 2013 and estimates this to reach US$273.0 million in 2019.

“With the increasing number of elderly and chronic disease patients, there is a marked shift in attitude from disease treatment to prevention,” said Frost & Sullivan Healthcare Consultant Poornima Srinivasan.

“Both patients and healthcare givers are seeking solutions that can aid in early diagnosis and regular monitoring, which, in turn, is driving the usage of diagnostic imaging services,” she added.

However, the market is somewhat constricted by the high capital expenditure on equipment. Hospitals and laboratories are also deterred by the service and maintenance costs of diagnostic imaging products such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), and Single Photon Emission CT (SPECT).

In addition, most diagnostic services, except for mammograms and colonoscopy, are not covered by the national insurance schemes in Singapore. Inadequate reimbursements tend to cause hospitals to defer their usage. Yet, consumer awareness regarding early diagnosis and intervention and the demand for low-radiation imaging equipment have made a strong case for sophisticated imaging technologies.

“The private outpatient diagnostic imaging market in Singapore is competing on technology and services rather than pricing,” noted Srinivasan.

“To retain their customer base and attract more customers, device manufacturers and service providers are aiming to invest in new technologies that can deliver more accurate results and a wider variety of tests,” she added.

Given the competitive nature of the market and end-user desire for novel, high-quality products, diagnostic imaging service providers with innovative technologies will flourish.

If you are interested in more information on this study, please send an e-mail to Melissa Tan, Corporate Communications, at melissa.tan@frost.com.

Singapore Private Outpatient Diagnostic Imaging Services Market is part of the Advanced Medical Technologies (http://www.medtech.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Drivers for Healthcare R&D Investment in Asia-Pacific, Technology Trends in Cardiac Imaging, Global Orthopedic Implant Market, and Multi-parameter Patient Monitoring Market in Asia-Pacific. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion 
Join Us:           Join our community 
Subscribe:       Newsletter on “the next big thing” 
Register:         Gain access to visionary innovation

Singapore Private Outpatient Diagnostic Imaging Services Market
9AB9

Contact:

Melissa Tan
Corporate Communications – Asia Pacific
P: +65 6890 0926
F: +65 6890 0999
E: melissa.tan@frost.com

Donna Jeremiah
Corporate Communications – Asia Pacific
P: +61 (02) 8247 8927
F: +61 (02) 9252 8066
E: djeremiah@frost.com

Carrie Low
Corporate Communications – Asia Pacific
P: +603 6204 5910
F: +603 6201 7402
E: carrie.low@frost.com

http://www.frost.com

Owen Mumford Wins Red Dot Award in Product Design for Uniquely Designed Unifine® Pentips® Plus Pen Needle

OXFORD, England, March 30, 2015 /PRNewswire/ —

Internationally renowned quality seal recognises leading medical device manufacturer in the area of product design 

On the awards’ 60th anniversary, Owen Mumford has been announced winner of the Red Dot Award in Product Design for its Unifine® Pentips® Plus pen needle, designed for the treatment of diabetes.

With its unique integrated disposal chamber, the Unifine® Pentips® has been carefully designed to encourage more frequent needle change and to reduce penetration and glide forces for a more comfortable injection experience. The medical device manufacturer won the award within the Product Design category which saw a total of 4,928 entries, from 56 countries, judged by a panel consisting of respected design professors, designers and specialist journalists.

Jarl Severn, CEO of Owen Mumford, commented, “We are both delighted and immensely proud to have been chosen for such a world renowned award for design. We have always focused on designing the next ‘big idea’ and have invested significantly in our Research and Development capabilities to support this.” Severn continued, “Our mission is to provide solutions that will exceed expectations, encourage adherence and improve quality of life; the Unifine® Pentips® Plus pen needle is a great demonstration of this, right from initial design concept through to manufacture.”

Richard Walker, Global Product Manager for Drug Delivery Products, added, “The initial concept behind Unifine® Pentips® Plus was to make the injection process as easy and comfortable for the end-user as possible, which plays an integral part in encouraging good self-management practices. The research and design team went back to the drawing board to create a completely new solution for the long established, standard insulin pen needle market sector. Unifine® Pentips® Plus is proven [1] to encourage better needle change behaviour and for our design to be recognised by the judging panel at Red Dot, is great news.”

The Unfine® Pentips® Plus pen needle is available in a range of lengths from 4mm 32G to 12mm 29G and available for sale in Europe, North America and Asia with our local China office launching Unifine® Pentips® Plus to their market this month.

For further information visit www.owenmumford.com

References: 

1. 2013 Independent study by Healthcare Research Worldwide: The impact of Unifine® Pentips® Plus on needle changing behaviour. 2014 Independent Melab GmbH Test Data.

About Owen Mumford 

Owen Mumford is a major medical device manufacturer that develops pioneering medical devices for its own Owen Mumford brand and custom device solutions for the world’s major pharmaceutical and diagnostic companies. Owen Mumford’s goal is to improve quality of life, encourage adherence to treatment and reduce healthcare costs. Making a world of difference, to a world of people.

With a history of world firsts in device solutions, Owen Mumford offers proven design, development and delivery services from a broad base of proven self-injection and blood sampling platform devices and intellectual property.

In business for over 60 years, Owen Mumford remains privately owned with a focus on long-term investment to deliver sustainable business growth. With a strong internal research and development capability, Owen Mumford’s goal is to develop solutions that address today’s healthcare demands. Through advanced research involving end-users and health care professionals, and extensive design and manufacturing capabilities, Owen Mumford produces class-leading medical devices that are used by a global audience – exporting over 85% of its products to more than 60 countries worldwide.

Selected as one of The World Economic Forum’s Global Growth Companies, Owen Mumford is a trusted partner to many of the world’s biggest medical device and pharmaceutical companies and works with international organisations to support customers at a local level and provide consistent and dedicated care.

For further information visit http://www.owenmumford.com/ or follow Owen Mumford on Facebook, Twitter and LinkedIn.

Media contacts 

Raman Sahota
Raman.Sahota@onebite.co.uk
Tel: +44(0)1635-887-696

Lily Hitchcock
lily.hitchcock@onebite.co.uk
Tel: +44(0)1635-887-672

Biosafe Goes Direct in Brazil, Acquiring Its Local Distributor

EYSINS, Switzerland, March 30, 2015 /PRNewswire/ — After a successful partnership of 10 years with its local distributor ACTS do Brasil Ltda., effective immediately Biosafe has acquired all ACTS’ Biosafe-related business, which has been spun off into a separate operating entity, Biosafe Brasil Distribuidora Ltda. Terms have not been disclosed.

This move will allow Biosafe to offer an extended range of benefits to customers in Brazil, including direct product support and service.

Today most public and private cord blood banks throughout the country already process with Biosafe’s proprietary Sepax technology, which is also used by a number of customers for regenerative medicine applications.

Olivier Waridel, CEO of the Biosafe Group, commented: “We firmly believe in the potential of the Brazilian market and this acquisition will further expand our  business  in our core markets of stem cell banking, regenerative medicine and bioprocessing. We look forward to strengthening our relationship with existing and future customers, and to assisting them with their development.”

Elsewhere in Latin America, Biosafe products are sold through distributors in Mexico, Argentina, Colombia and Chile. Biosafe plans to extend the network to additional countries in the near future.

About the Biosafe Group   

Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and Sao Paulo) and is present in more than 50 countries, either directly or through distributors.

For further information:

Christopher Bolton
CFO
Biosafe Group SA
+41-22-365-27-27
christopher.bolton@biosafe.ch
http://www.biosafe.ch